Tuesday, March 31, 2020 8:32:47 PM
I completely missed the need for big pharma to have this decision overturned. Just like their need to see Amarin win the first amendment fight with the FDA. Forget the settlement route and quick buyout, the big guys need this decision overturned ASAP. It also looks better in the court of public opinion if the win is gained by the smaller innovative company and not the big bad guys. So I think they need to pay for a ticket to the party and this is what I suggest:
1) one or more BPs acquire 25% of Amarin on the open market (400 million is lobby money for them).
2) use their influence to fast track the case because they want killed A
SAP. Keep in mind as minority investors the FDA will be more accommodating to Amarin. Why, retired FDA employees go to work for BP.
3) no insider sales until litigation is resolved (decision) and BP has to hold their position through litigation.
4) sales and marketing agreement with the investing BPs for the EU.
5) license Russia and other Eastern European countries.
6) just to piss off Reddy, license India to a Chinese company.
7) license all other markets your minority investor does not want.
8) Replace JT with an interim CEO from the board
9) you win then you sell to the highest bidder, you lose and you sell for the value of cash flow from the parts.
If they do this the stock will get back to the low teens and will be insulted from manipulation because 25% is in strong hands.
1) one or more BPs acquire 25% of Amarin on the open market (400 million is lobby money for them).
2) use their influence to fast track the case because they want killed A
SAP. Keep in mind as minority investors the FDA will be more accommodating to Amarin. Why, retired FDA employees go to work for BP.
3) no insider sales until litigation is resolved (decision) and BP has to hold their position through litigation.
4) sales and marketing agreement with the investing BPs for the EU.
5) license Russia and other Eastern European countries.
6) just to piss off Reddy, license India to a Chinese company.
7) license all other markets your minority investor does not want.
8) Replace JT with an interim CEO from the board
9) you win then you sell to the highest bidder, you lose and you sell for the value of cash flow from the parts.
If they do this the stock will get back to the low teens and will be insulted from manipulation because 25% is in strong hands.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
